Nascent Pharma Holdings, Inc. has completed the Financial Industry Regulatory Authority processing for its corporate name change from Can B Corp. to Nascent Pharma Holdings, Inc. and trading symbol change from "CANB" to "NASC," effective September 16, 2025. The company's common stock now trades under the new symbol with CUSIP number 63108T105, following a holding company reorganization completed in October 2024 that established Nascent Pharma Holdings as the parent company of Can B Corp.
The corporate restructuring reflects the company's strategic positioning as a pharmaceutical intellectual property company focused on maximizing the value of its cannabis patent portfolios. Nascent Pharma Holdings owns two issued patents registered with the US Patent and Trademark Office covering cannabis extracts and methods of preparation, with emphasis on both composition and use applications. This intellectual property foundation positions the company within the growing cannabis pharmaceutical sector, where patent protection plays a critical role in establishing market advantage and valuation.
The name and symbol change carries significant implications for investors and the broader cannabis industry. By transitioning from Can B Corp. to Nascent Pharma Holdings, the company signals its evolution from a general cannabis business to a specialized pharmaceutical IP entity. This shift aligns with increasing investor interest in companies with protected intellectual property in the cannabis space, particularly as the industry matures and faces greater regulatory scrutiny. The change may enhance the company's ability to attract pharmaceutical industry partnerships and investment, given the clearer focus on patent-driven value creation.
For the cannabis and psychedelics industries, Nascent Pharma Holdings' emphasis on patent protection represents a growing trend toward intellectual property consolidation and monetization. As these industries continue to develop and face potential federal legalization, companies with strong patent portfolios may gain competitive advantages in licensing, partnerships, and market positioning. The company's forward-looking statements acknowledge the inherent risks and uncertainties in achieving these objectives, including economic, competitive, and regulatory factors that could impact operations and patent valuation. The corporate changes position Nascent Pharma Holdings to potentially capitalize on the expanding market for cannabis-based pharmaceutical products while navigating the complex intellectual property landscape.
